sudhl5 Search Results


sudhl5  (DSMZ)
93
DSMZ sudhl5
Sudhl5, supplied by DSMZ, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sudhl5/SU-DHL-5/10__1158_slash_0008___5472__can___16___1793-34-19-27
Average 93 stars, based on 1 article reviews
sudhl5 - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier
b cell lymphoma cell line sudhl 5  (ATCC)
95
ATCC b cell lymphoma cell line sudhl 5
B Cell Lymphoma Cell Line Sudhl 5, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sudhl5/SU-DHL-5/pm25912635-42-1-40
Average 95 stars, based on 1 article reviews
b cell lymphoma cell line sudhl 5 - by Bioz Stars, 2026-09
95/100 stars
  Buy from Supplier
ros 50  (DSMZ)
90
DSMZ ros 50
Ros 50, supplied by DSMZ, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sudhl5/ROS-50/pm30971826-744-23-10
Average 90 stars, based on 1 article reviews
ros 50 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
diffuse large b cell lymphoma  (DSMZ)
95
DSMZ diffuse large b cell lymphoma
Diffuse Large B Cell Lymphoma, supplied by DSMZ, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sudhl5/SU-DHL-4/pmc08533740-24-8-20
Average 95 stars, based on 1 article reviews
diffuse large b cell lymphoma - by Bioz Stars, 2026-09
95/100 stars
  Buy from Supplier
dlbcl cell lines  (DSMZ)
95
DSMZ dlbcl cell lines
Figure 2. Iron chelators and ironomycin inhibit <t>DLBCL</t> <t>cell</t> growth and decrease the LIP. A–C, DLBCL cells were incubated with different concentrations of iron chelators or vehicle for 96 hours. IC50 was calculated with concentration–response curve after treatment with deferoxamine (A), deferasirox (B), and ironomycin (C). D, Cell viability was examined using quantification of ATP assay. Data are expressed as mean percentage SEM of at least three independent experiments performed in six times. Balb/c mice were inoculated with murine A20 lymphoma cells and when tumor was palpable, the mice were treated with ironomycin (3 mg/kg i.p.). Mice were sacrificed when tumor volume reached 1,500 mm3. Evaluation of the tumor volume of vehicle (n ¼ 10) and ironomycin-treated mice (n ¼ 10). , P < 0.05 using Mann– Whitney test. E, Effect of Ironomycin on LIP was measured by dequenching of Calcein. Cells were loaded with 0.25 mmol/L Calcein-AM for 15 min, washed, and incubated for 1 hour with or without 100 mmol/L deferasirox or 10 mmol/L ironomycin. In this experiment, following treatment, cells were washed and their fluorescence was measured by flow cytometry. The difference in the mean fluorescence index between chelator-treated and untreated cells (DF) is presented. The results represent the mean and SD of at least four independent experiments.
Dlbcl Cell Lines, supplied by DSMZ, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sudhl5/U-2932/pm35078814-64-6-31
Average 95 stars, based on 1 article reviews
dlbcl cell lines - by Bioz Stars, 2026-09
95/100 stars
  Buy from Supplier
dlbcl cell lines  (ATCC)
96
ATCC dlbcl cell lines
Figure 2. CD39 expression discriminates between GCB and ABC <t>DLBCL</t> primary tumors and cell lines. Cluster gram showing the expression of MME, BCL6, ENTPD1, and BCL2 genes in ABC DLBCL samples (n = 167) and GCB DLBCL samples (n = 183) in the ABC and GCB DLBCL samples from the R-CHOP and CHOP Lenz cohorts (gene expression profile, GEP, data) (a). (B) Boxplots illustrate the expression signal (GEP) of ENPD1 in ABC DLBCL samples and in GCB DLBCL samples in the Lenz cohort (b). Boxplots showing CD39 mean fluorescence intensity (MFI, logarithmic scale) in 16 DLBCL derived-cell lines (c). The boxes indicate the 25th and 75th percentile values. The line in the middle corresponds to the median. The vertical lines, to the 10th and the 90th percentiles. The outliers are identified as the third quartile plus 1.5 IQR (interquartile range); * p-value < 0.05 (Mann-Whitney U-test). GCB: germinal center B cell–like, ABC: Activated B cell–like, DLBCL: diffuse large B cell lymphoma.
Dlbcl Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sudhl5/SU-DHL-4/pm31336593-31-2-26
Average 96 stars, based on 1 article reviews
dlbcl cell lines - by Bioz Stars, 2026-09
96/100 stars
  Buy from Supplier
sudhl4  (CEM Corporation)
90
CEM Corporation sudhl4
Figure 2. CD39 expression discriminates between GCB and ABC <t>DLBCL</t> primary tumors and cell lines. Cluster gram showing the expression of MME, BCL6, ENTPD1, and BCL2 genes in ABC DLBCL samples (n = 167) and GCB DLBCL samples (n = 183) in the ABC and GCB DLBCL samples from the R-CHOP and CHOP Lenz cohorts (gene expression profile, GEP, data) (a). (B) Boxplots illustrate the expression signal (GEP) of ENPD1 in ABC DLBCL samples and in GCB DLBCL samples in the Lenz cohort (b). Boxplots showing CD39 mean fluorescence intensity (MFI, logarithmic scale) in 16 DLBCL derived-cell lines (c). The boxes indicate the 25th and 75th percentile values. The line in the middle corresponds to the median. The vertical lines, to the 10th and the 90th percentiles. The outliers are identified as the third quartile plus 1.5 IQR (interquartile range); * p-value < 0.05 (Mann-Whitney U-test). GCB: germinal center B cell–like, ABC: Activated B cell–like, DLBCL: diffuse large B cell lymphoma.
Sudhl4, supplied by CEM Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sudhl5/sudhl4/10__1182_slash_blood__v92__9__3410-39-29-14
Average 90 stars, based on 1 article reviews
sudhl4 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results


Figure 2. Iron chelators and ironomycin inhibit DLBCL cell growth and decrease the LIP. A–C, DLBCL cells were incubated with different concentrations of iron chelators or vehicle for 96 hours. IC50 was calculated with concentration–response curve after treatment with deferoxamine (A), deferasirox (B), and ironomycin (C). D, Cell viability was examined using quantification of ATP assay. Data are expressed as mean percentage SEM of at least three independent experiments performed in six times. Balb/c mice were inoculated with murine A20 lymphoma cells and when tumor was palpable, the mice were treated with ironomycin (3 mg/kg i.p.). Mice were sacrificed when tumor volume reached 1,500 mm3. Evaluation of the tumor volume of vehicle (n ¼ 10) and ironomycin-treated mice (n ¼ 10). , P < 0.05 using Mann– Whitney test. E, Effect of Ironomycin on LIP was measured by dequenching of Calcein. Cells were loaded with 0.25 mmol/L Calcein-AM for 15 min, washed, and incubated for 1 hour with or without 100 mmol/L deferasirox or 10 mmol/L ironomycin. In this experiment, following treatment, cells were washed and their fluorescence was measured by flow cytometry. The difference in the mean fluorescence index between chelator-treated and untreated cells (DF) is presented. The results represent the mean and SD of at least four independent experiments.

Journal: Cancer research

Article Title: Targeting Cellular Iron Homeostasis with Ironomycin in Diffuse Large B-cell Lymphoma.

doi: 10.1158/0008-5472.CAN-21-0218

Figure Lengend Snippet: Figure 2. Iron chelators and ironomycin inhibit DLBCL cell growth and decrease the LIP. A–C, DLBCL cells were incubated with different concentrations of iron chelators or vehicle for 96 hours. IC50 was calculated with concentration–response curve after treatment with deferoxamine (A), deferasirox (B), and ironomycin (C). D, Cell viability was examined using quantification of ATP assay. Data are expressed as mean percentage SEM of at least three independent experiments performed in six times. Balb/c mice were inoculated with murine A20 lymphoma cells and when tumor was palpable, the mice were treated with ironomycin (3 mg/kg i.p.). Mice were sacrificed when tumor volume reached 1,500 mm3. Evaluation of the tumor volume of vehicle (n ¼ 10) and ironomycin-treated mice (n ¼ 10). , P < 0.05 using Mann– Whitney test. E, Effect of Ironomycin on LIP was measured by dequenching of Calcein. Cells were loaded with 0.25 mmol/L Calcein-AM for 15 min, washed, and incubated for 1 hour with or without 100 mmol/L deferasirox or 10 mmol/L ironomycin. In this experiment, following treatment, cells were washed and their fluorescence was measured by flow cytometry. The difference in the mean fluorescence index between chelator-treated and untreated cells (DF) is presented. The results represent the mean and SD of at least four independent experiments.

Article Snippet: Human DLBCL cell lines The 16 DLBCL cell lines (U2932, OCI-LY-3, NU-DHL-1, OCI-LY19, DB, SUDHL4, OCILY1, SUDHL5, DOHH2, SUDHL10, HT, RI-1, SU-DHL-6, NUDUL-1, WSU-DLCL-2 and OCI-LY-7) were purchased from theDSMZ (Leibniz-Institut DSMZ -Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH).

Techniques: Incubation, Concentration Assay, ATP Assay, MANN-WHITNEY, Cytometry

Figure 4. Iron chelators and ironomycin induce ROS production in DLBCL cells. A and B, Effect of deferoxamine, deferasirox, and ironomycin on the ROS production was analyzed using flow cytometry after oxidation of a CM-H2DFDA probe for OCI-LY3 (A) and DB cell line (B) at 48 hours. C, Vehicle and GSH treatment (5 and 0.5 mmol/L, respectively, 1 hour) was used as a negative control and oxygen peroxide (10 mmol/L, 1 hour) as a positive control. For the ROS reversion assay, DB cells were treated with 250 nmol/L Ironomycin for 48 hours with or without GSH or Fer-1 or deferoxamine (DFO). ROS production was analyzed using flow cytometry after oxidation of a CM-H2DFDA probe. Chaetocin and erastin were used as positive control for GSH and Fer-1 reversion, respectively. Results represent the mean percentage and SD of three independent experiments. , P < 0.05; , P < 0.01; , P < 0.001; , P < 0.0001; NS, nonsignificant; with paired Student t test.

Journal: Cancer research

Article Title: Targeting Cellular Iron Homeostasis with Ironomycin in Diffuse Large B-cell Lymphoma.

doi: 10.1158/0008-5472.CAN-21-0218

Figure Lengend Snippet: Figure 4. Iron chelators and ironomycin induce ROS production in DLBCL cells. A and B, Effect of deferoxamine, deferasirox, and ironomycin on the ROS production was analyzed using flow cytometry after oxidation of a CM-H2DFDA probe for OCI-LY3 (A) and DB cell line (B) at 48 hours. C, Vehicle and GSH treatment (5 and 0.5 mmol/L, respectively, 1 hour) was used as a negative control and oxygen peroxide (10 mmol/L, 1 hour) as a positive control. For the ROS reversion assay, DB cells were treated with 250 nmol/L Ironomycin for 48 hours with or without GSH or Fer-1 or deferoxamine (DFO). ROS production was analyzed using flow cytometry after oxidation of a CM-H2DFDA probe. Chaetocin and erastin were used as positive control for GSH and Fer-1 reversion, respectively. Results represent the mean percentage and SD of three independent experiments. , P < 0.05; , P < 0.01; , P < 0.001; , P < 0.0001; NS, nonsignificant; with paired Student t test.

Article Snippet: Human DLBCL cell lines The 16 DLBCL cell lines (U2932, OCI-LY-3, NU-DHL-1, OCI-LY19, DB, SUDHL4, OCILY1, SUDHL5, DOHH2, SUDHL10, HT, RI-1, SU-DHL-6, NUDUL-1, WSU-DLCL-2 and OCI-LY-7) were purchased from theDSMZ (Leibniz-Institut DSMZ -Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH).

Techniques: Cytometry, Negative Control, Positive Control

Figure 7. Ironomycin presents a significant toxicity on DLBCL primary cells and potentializes doxorubicin cytotoxicity. A, Primary DLBCL cells were treated with ironomycin and/or doxorubicin and incubated during 96 hours with CD40L. DLBCL cell toxicity was analyzed by flow cytometry. B, Hematopoietic progenitor CFU assay were performed with CD34þ cells from apheresis of 5 donors. Cells were cultured in hydroxyl-methyl-cellulose medium with or without conventional chemotherapy or ironomycin. CFU-C, CFU-E, and CFU-GM were counted after 14-day culture. C, The toxicity of ironomycin alone or in combination with doxorubicin on normal CD3þ cells was assessed by flow cytometry. Results represent the median interquartile ranges of each population (n ¼ 5 patients). Statistical significance was tested using t test of pairs: , P < 0.05; , P < 0.01; , P < 0.001; , P < 0.0001. D, Primary DLBCL cells of 6 patients and PBMC of a healthy donor were incubated with 5 mmol/L Rho-Nox1 Fe2þ probe. The MFI was assessed by flow cytometry in CD20þ DLBCL cells and CD20 cells (microenvironment cells). E, DB cells were treated with increasing concentrations of ironomycin com- bined with doxorubicin for 96 hours, and cell viability was tested by ATP quantification to obtain the viability matrix. The synergy matrix was calculated as described in Materials and Methods.

Journal: Cancer research

Article Title: Targeting Cellular Iron Homeostasis with Ironomycin in Diffuse Large B-cell Lymphoma.

doi: 10.1158/0008-5472.CAN-21-0218

Figure Lengend Snippet: Figure 7. Ironomycin presents a significant toxicity on DLBCL primary cells and potentializes doxorubicin cytotoxicity. A, Primary DLBCL cells were treated with ironomycin and/or doxorubicin and incubated during 96 hours with CD40L. DLBCL cell toxicity was analyzed by flow cytometry. B, Hematopoietic progenitor CFU assay were performed with CD34þ cells from apheresis of 5 donors. Cells were cultured in hydroxyl-methyl-cellulose medium with or without conventional chemotherapy or ironomycin. CFU-C, CFU-E, and CFU-GM were counted after 14-day culture. C, The toxicity of ironomycin alone or in combination with doxorubicin on normal CD3þ cells was assessed by flow cytometry. Results represent the median interquartile ranges of each population (n ¼ 5 patients). Statistical significance was tested using t test of pairs: , P < 0.05; , P < 0.01; , P < 0.001; , P < 0.0001. D, Primary DLBCL cells of 6 patients and PBMC of a healthy donor were incubated with 5 mmol/L Rho-Nox1 Fe2þ probe. The MFI was assessed by flow cytometry in CD20þ DLBCL cells and CD20 cells (microenvironment cells). E, DB cells were treated with increasing concentrations of ironomycin com- bined with doxorubicin for 96 hours, and cell viability was tested by ATP quantification to obtain the viability matrix. The synergy matrix was calculated as described in Materials and Methods.

Article Snippet: Human DLBCL cell lines The 16 DLBCL cell lines (U2932, OCI-LY-3, NU-DHL-1, OCI-LY19, DB, SUDHL4, OCILY1, SUDHL5, DOHH2, SUDHL10, HT, RI-1, SU-DHL-6, NUDUL-1, WSU-DLCL-2 and OCI-LY-7) were purchased from theDSMZ (Leibniz-Institut DSMZ -Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH).

Techniques: Incubation, Cytometry, Colony-forming Unit Assay, Cell Culture

Figure 8. Ironomycin induces mortality and TFR1 downregulation in primary DLBCL cells. A, Primary DLBCL cells from four patients were cultured with recombinant CD40 L in the presence or absence of ironomycin (500 nmol/L). After 96 hours, cell death of DLBCL cells was monitored by Annexin V/PI staining using flow cytometry. Results represent the mean SD. B, Primary samples of patients with DLBCL were cultured with recombinant CD40 L in presence or absence ironomycin (500 nmol/L). DLBCL cell membrane TFR1 (CD71) expression was assessed by flow cytometry. , P < 0.05; , P < 0.01.

Journal: Cancer research

Article Title: Targeting Cellular Iron Homeostasis with Ironomycin in Diffuse Large B-cell Lymphoma.

doi: 10.1158/0008-5472.CAN-21-0218

Figure Lengend Snippet: Figure 8. Ironomycin induces mortality and TFR1 downregulation in primary DLBCL cells. A, Primary DLBCL cells from four patients were cultured with recombinant CD40 L in the presence or absence of ironomycin (500 nmol/L). After 96 hours, cell death of DLBCL cells was monitored by Annexin V/PI staining using flow cytometry. Results represent the mean SD. B, Primary samples of patients with DLBCL were cultured with recombinant CD40 L in presence or absence ironomycin (500 nmol/L). DLBCL cell membrane TFR1 (CD71) expression was assessed by flow cytometry. , P < 0.05; , P < 0.01.

Article Snippet: Human DLBCL cell lines The 16 DLBCL cell lines (U2932, OCI-LY-3, NU-DHL-1, OCI-LY19, DB, SUDHL4, OCILY1, SUDHL5, DOHH2, SUDHL10, HT, RI-1, SU-DHL-6, NUDUL-1, WSU-DLCL-2 and OCI-LY-7) were purchased from theDSMZ (Leibniz-Institut DSMZ -Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH).

Techniques: Cell Culture, Recombinant, Staining, Cytometry, Membrane, Expressing

Figure 2. CD39 expression discriminates between GCB and ABC DLBCL primary tumors and cell lines. Cluster gram showing the expression of MME, BCL6, ENTPD1, and BCL2 genes in ABC DLBCL samples (n = 167) and GCB DLBCL samples (n = 183) in the ABC and GCB DLBCL samples from the R-CHOP and CHOP Lenz cohorts (gene expression profile, GEP, data) (a). (B) Boxplots illustrate the expression signal (GEP) of ENPD1 in ABC DLBCL samples and in GCB DLBCL samples in the Lenz cohort (b). Boxplots showing CD39 mean fluorescence intensity (MFI, logarithmic scale) in 16 DLBCL derived-cell lines (c). The boxes indicate the 25th and 75th percentile values. The line in the middle corresponds to the median. The vertical lines, to the 10th and the 90th percentiles. The outliers are identified as the third quartile plus 1.5 IQR (interquartile range); * p-value < 0.05 (Mann-Whitney U-test). GCB: germinal center B cell–like, ABC: Activated B cell–like, DLBCL: diffuse large B cell lymphoma.

Journal: Journal of clinical medicine

Article Title: Phenotypic Characterization of Diffuse Large B-Cell Lymphoma Cells and Prognostic Impact.

doi: 10.3390/jcm8071074

Figure Lengend Snippet: Figure 2. CD39 expression discriminates between GCB and ABC DLBCL primary tumors and cell lines. Cluster gram showing the expression of MME, BCL6, ENTPD1, and BCL2 genes in ABC DLBCL samples (n = 167) and GCB DLBCL samples (n = 183) in the ABC and GCB DLBCL samples from the R-CHOP and CHOP Lenz cohorts (gene expression profile, GEP, data) (a). (B) Boxplots illustrate the expression signal (GEP) of ENPD1 in ABC DLBCL samples and in GCB DLBCL samples in the Lenz cohort (b). Boxplots showing CD39 mean fluorescence intensity (MFI, logarithmic scale) in 16 DLBCL derived-cell lines (c). The boxes indicate the 25th and 75th percentile values. The line in the middle corresponds to the median. The vertical lines, to the 10th and the 90th percentiles. The outliers are identified as the third quartile plus 1.5 IQR (interquartile range); * p-value < 0.05 (Mann-Whitney U-test). GCB: germinal center B cell–like, ABC: Activated B cell–like, DLBCL: diffuse large B cell lymphoma.

Article Snippet: The 16 DLBCL cell lines (DOHH2, HT, OCI-LY19, DB, OCI-LY1, SUDHL-4, SUDHL-5, SUDHL-10, NUDHL-1, OCI-LY7, WSU-DLCL2, SUDHL-6, NUDUL-1, U2932, OCI-LY3, and RI-1) were purchased from the American Type Culture Collection or from DSMZ (Leibniz-Institut DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Germany).

Techniques: Expressing, Gene Expression, Derivative Assay, MANN-WHITNEY

Figure 6. BCL6 expression correlates with the response to etoposide in DLBCL cell lines. Box-plots illustrate the inhibitory concentration 50 (IC50) of etoposide on a logarithmic scale. The boxes represent the 25th and 75th percentile values. The line in the middle corresponds to the median. The vertical lines correspond to the 10th and the 90th percentiles, and the circles, to the outliers. * p value < 0.05 (Mann-Whitney U-test) (a). Linear regression analysis of BCL6 expression (MFI) in function of the IC50 of etoposide in 16 DLBCL cell lines. r represents the Spearman correlation coefficient, p value <0.05 (Spearman correlation test) (b).

Journal: Journal of clinical medicine

Article Title: Phenotypic Characterization of Diffuse Large B-Cell Lymphoma Cells and Prognostic Impact.

doi: 10.3390/jcm8071074

Figure Lengend Snippet: Figure 6. BCL6 expression correlates with the response to etoposide in DLBCL cell lines. Box-plots illustrate the inhibitory concentration 50 (IC50) of etoposide on a logarithmic scale. The boxes represent the 25th and 75th percentile values. The line in the middle corresponds to the median. The vertical lines correspond to the 10th and the 90th percentiles, and the circles, to the outliers. * p value < 0.05 (Mann-Whitney U-test) (a). Linear regression analysis of BCL6 expression (MFI) in function of the IC50 of etoposide in 16 DLBCL cell lines. r represents the Spearman correlation coefficient, p value <0.05 (Spearman correlation test) (b).

Article Snippet: The 16 DLBCL cell lines (DOHH2, HT, OCI-LY19, DB, OCI-LY1, SUDHL-4, SUDHL-5, SUDHL-10, NUDHL-1, OCI-LY7, WSU-DLCL2, SUDHL-6, NUDUL-1, U2932, OCI-LY3, and RI-1) were purchased from the American Type Culture Collection or from DSMZ (Leibniz-Institut DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Germany).

Techniques: Expressing, Concentration Assay, MANN-WHITNEY